Equities

Indoco Remedies Ltd

INDOCO:NSI

Indoco Remedies Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)328.05
  • Today's Change4.00 / 1.23%
  • Shares traded34.75k
  • 1 Year change+5.19%
  • Beta0.6175
Data delayed at least 15 minutes, as of Apr 26 2024 10:20 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Indoco Remedies Limited is an India-based manufacturer of pharmaceutical products. The Company is engaged in the manufacturing and marketing of formulations (finished dosage forms) and active pharmaceutical ingredients (APIs). The Company offers medicines in multiple therapeutic categories, such as diabetology, respiratory, stomatology, women's health, nutritional products, gastroenterology, cardiology, metabolic disorders and primary care medicine. Its products/brands include Cyclopam, Sensodent-K, Karvol Plus, Sensoform, Cital UTI, Kidodent, Rexidin M, Lignox A, Dentogel, Aloja, Homide, Renolen, Noxa, Dexoren - S, Aloja M, ATM, Febrex Plus, Sensodent-KF, SM Fibro, MCBM 69, Cal Aid, Snowdent, Dropizin, Zincoren, Coloferrin, Bfloren, RR Sensoform Dental, Mofloren-D, and Tuspel among others. The Company caters to both domestic and international markets. Its subsidiaries include Xtend Industrial Designers and Engineers Pvt Ltd, Indoco Remedies Czech sro, and Indoco Remedies UK Limited.

  • Revenue in INR (TTM)17.96bn
  • Net income in INR1.02bn
  • Incorporated1947
  • Employees6.10k
  • Location
    Indoco Remedies Ltd166 Indoco HouseCst Road, Santacruz EastMUMBAI 400098IndiaIND
  • Phone+91 2 226541851
  • Fax+91 2 226523980
  • Websitehttps://www.indoco.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
INDOCO:NSI since
announced
Transaction
value
FPP Holding Co LLCAnnounced06 Jun 202306 Jun 2023Announced-1.93%4.00m
Data delayed at least 15 minutes, as of Apr 26 2024 10:20 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Themis Medicare Ltd3.64bn452.86m19.34bn996.0042.78--33.775.314.914.9139.49--------3,655,101.00--9.59--14.9465.5860.1312.4413.15------7.33-10.2110.85-21.9338.1824.51--
Amrutanjan Health Care Ltd3.94bn440.09m19.92bn575.0045.58--39.975.0515.1315.13135.41--------6,860,612.00--17.04--21.2249.5154.0811.1613.37--341.76--17.21-6.4611.37-40.7114.7223.8710.64
Solara Active Pharma Sciences Ltd14.07bn-3.08bn20.19bn2.36k------1.43-85.65-85.65390.73--------5,958,916.00--2.68--4.1040.4744.49-21.884.58---1.67--10.1013.8322.6161.86--26.23--
Suven Life Sciences Ltd119.19m-1.06bn24.77bn132.00------207.85-5.20-5.200.5759--------902,939.40---31.29---35.32--66.93-890.87-127.02---744.27----14.31-53.543.06---41.37--
Jeena Sikho Lifecare Ltd-100.00bn-100.00bn25.19bn1.23k--79.68----------12.72------------------------0.8228--0.2681--43.84--77.37------
Morepen Laboratories Ltd16.31bn761.19m25.58bn1.65k33.16--23.921.571.511.5132.53--------9,891,111.00--7.39--13.7835.8532.824.675.19--27.34--0.00-8.3618.51-61.965.5011.33--
RPG Life Sciences Limited5.74bn847.70m25.61bn1.17k30.22--25.304.4751.2651.26346.80------------13.08--18.2668.1762.4214.789.71--296.86--29.2616.518.1231.3938.1316.1537.97
Innova Captab Ltd-100.00bn-100.00bn27.01bn--------------------------------------------------15.72--6.26------
Indoco Remedies Ltd17.96bn1.02bn29.87bn6.10k29.65--16.231.6610.9310.93192.26--------2,943,454.00--6.07--8.9069.3965.355.616.30--5.11--14.798.309.81-8.1128.158.2517.61
SeQuent Scientific Ltd13.75bn-1.29bn31.12bn478.00------2.26-5.18-5.1855.33--------28,769,920.00--2.33--3.6742.7842.47-8.972.59---0.3894--17.270.572810.84-395.83--12.88--
Gufic BioSciences Ltd7.85bn841.95m32.16bn1.63k37.20--30.494.108.628.6280.38--------4,820,074.00--12.30--23.0851.0844.9110.739.84--8.22--1.39-11.3617.47-16.8437.0686.8214.87
Supriya Lifescience Ltd5.54bn1.20bn33.30bn392.0027.64--24.616.0114.9714.9768.93--------14,144,410.00--20.77--29.0661.9455.8321.7224.33--63.63--2.02-13.0416.70-40.8159.4185.55--
Dishman Carbogen Amcis Ltd25.80bn-1.54bn36.59bn1.30k----24.831.42-9.84-9.84164.35--------19,919,850.00--0.4699--0.566576.9374.36-5.981.82---0.1245--202.7612.727.32-265.46--21.54--
Hikal Ltd18.16bn716.22m38.06bn2.14k53.18--20.712.105.805.80147.17--------8,477,077.00--5.86--8.8752.0845.413.946.37--2.78--10.144.139.25-51.160.297323.354.42
Data as of Apr 26 2024. Currency figures normalised to Indoco Remedies Ltd's reporting currency: Indian Rupee INR

Institutional shareholders

18.37%Per cent of shares held by top holders
HolderShares% Held
Nippon Life India Asset Management Ltd. (Invt Mgmt)as of 31 Mar 20244.58m4.97%
quant Money Managers Ltd.as of 31 Mar 20244.20m4.56%
ICICI Prudential Asset Management Co. Ltd.as of 31 Mar 20241.75m1.90%
DSP Asset Managers Pvt. Ltd.as of 31 Mar 20241.69m1.84%
HDFC Asset Management Co. Ltd. (Invt Mgmt)as of 31 Mar 20241.50m1.63%
Franklin Templeton Asset Management (India) Pvt Ltd.as of 31 Mar 20241.36m1.48%
UTI Asset Management Co. Ltd. (Investment Management)as of 31 Mar 2024969.52k1.05%
Dimensional Fund Advisors LPas of 04 Apr 2024480.65k0.52%
Tata Asset Management Ltd.as of 31 Mar 2024276.85k0.30%
Sundaram Asset Management Co. Ltd.as of 31 Mar 2024110.59k0.12%
More ▼
Data from 31 Dec 2023 - 18 Apr 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.